Navigation Links
Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions

BURLINGAME, Calif., Dec. 21, 2011 /PRNewswire/ -- Epitomics, Inc., a California based biotech company, announced today that they have successfully completed a Star Program in collaboration with the University of California, Davis, which has resulted in the application of a new, advanced antibody assay technique, a label-free optical microarray detection platform, for high-throughput measurements of antibody-antigen interactions. Over the course of the project, more than 100 rabbit monoclonal antibodies (RabMAbs) raised against clinical cancer biomarkers were analyzed and determined to possess affinities ranging from 10-9 to 10-13 M, with an average of 10-10 M. The affinity values measured using this label-free optical microarray detection process were found to be consistent with those measured using the established BIAcore technology, based on a random sampling of the RabMAb population.

"I am very excited about our new technology which can provide consistent results compared to the established BIAcore technology but in a high throughput manner.  I am also impressed with high affinities of RabMAbs," said Dr. Xiangdong Zhu, a Professor in Physics at the University of California, Davis, who was the inventor of the label-free optical microarray detection technology used in the program.

"It is widely accepted that rabbits produce higher affinity antibodies than mice, but this had not previously been demonstrated with a large population of monoclonal antibodies. With the availability of this novel technology, we were able to demonstrate that RabMAbs have consistently high affinities through the measurement of a large collection of RabMAbs," said Dr. Guo-Liang Yu, CEO, Epitomics, Inc.

About Epitomics
Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity, specificity and bioactivity both in vitro and in vivo. Epitomics, Inc. is headquartered in Burlingame, California, and operates wholly owned subsidiaries in Hong Kong and Hangzhou, the People's Republic of China.  For more information about Epitomics, please visit

SOURCE Epitomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a Novel Method for Identifying Differentially Expressed Proteins
2. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
3. HistoRx Licenses Melanoma Assay from Yale University
4. Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study
5. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
6. Arizona State University engineers aim to improve performance of technology in extreme environments
7. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
8. IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri
9. University of Toronto engineers solve energy puzzle
10. The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medicals ALFApump® System
11. University of Toronto researchers create worlds most efficient flexible OLED on plastic
Post Your Comments:
(Date:12/1/2015)... -- Symic, a clinical-stage biotherapeutics company developing multiple compounds that ... that it has secured $25 million in a Series ... lead candidates SB-030 and SB-061. The financing was led ... existing major investors, as well as several new investors. ... Symic to over $43 million since being founded in ...
(Date:12/1/2015)... Austin, Texas (PRWEB) , ... December 01, 2015 , ... ... In his new post, VerMilyea will oversee all IVF lab procedures as ... analysis and fertility preservation. , “We traveled 7,305 miles to Auckland, New Zealand to ...
(Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group today ... Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with the ... medical researchers and practitioners, experienced in administering stem cell protocols using highly manipulated ...
(Date:11/30/2015)... Partnership includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ... up through cost cuts of priority ... licensees based anywhere in the world will have the right to make, use and ... , where licensees based anywhere in the world will have the right to make, ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... , October 29, 2015 ... authentication company focused on the growing mobile commerce ... announces that StackCommerce, a leading marketplace to discover ... the Wocket® smart wallet on StackSocial for this ... ("NXT-ID" or the "Company"), a biometric authentication company ...
Breaking Biology News(10 mins):